

Dear Prof. Pourmand,

Congratulations, your abstract has been accepted for presentation during the 32nd Annual EAU Congress London

Your presentation is scheduled in the following session:

Session title: **Rare... but important diseases**

Session type: **Poster Session 67**

Presentation type: **Standard presentation**

Date: **Monday, 27 March 2017 from 12:15 to 13:45**

Room: **Room Stockholm (Boulevard, level 1)**

Please check the abstract title and the order of the authors below very carefully. This is the way your abstract will be printed in all further publications. If you have any changes please e-mail to: abstracts@congressconsultants.com.

Note: All accepted abstracts have been re-numbered. The abstract number below is the new number. From now on please use this new number on posters and/or slides.

Abstract ID Number: **AM17-1124**

New Number: **889**

Abstract Title: **Encapsulating peritoneal sclerosis, a serious complication of peritoneal dialysis**

Authors: **G. Pourmand¹, S. Alatab¹, I. Najafi², M. Hosseini³, N. Ahmadbeigi⁴**

(1) Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, (2) Tehran University of Medical Sciences, Shariati Hospital, Nephrology Research Center, Tehran, Iran, (3) Tehran University of Medical Sciences, School of Public Health, Tehran, Iran, (4) Tehran University of Medical Sciences, Digestive Disease Research Institute, Liver and Pancreatobiliary Diseases Research Center, Tehran, Iran

Body:

Introduction & Objectives Chronic Kidney disease is major health issues that might lead to End Stage Renal Disease in which patients need renal replacement therapy (RRT) in order to survive. Peritoneal dialysis (PD) offers the healthiest way for starting RRT, however exposes long term PD patients to a dangerous high mortality complication named Encapsulating peritoneal sclerosis (EPS). In this study we searched for possible risk factors of EPS.

Material & Methods Data were collected from two PD centers (shafa and Shariati) covering period 1995 to 2012 and comprised 464 patients. Control group defined as PD patients stayed on PD > 42 month (n=122), and case group was 12 confirmed EPS patients. Associations were analyzed using linear regression analysis with EPS being primary outcome.

Results Prevalence and incidence of EPS were 2.59% and 8.9 with an incidence of 0.7% patient-years, respectively. The age at start of PD in EPS patients (32.75±10.8 year) was significantly lower compared with control group (49.61±16.18 year, p=0.0001). The mean duration of PD in EPS and control group were 2494.4±940.9 and 1890.2±598.8 days (p= 0.002). Control group had 145 episodes of peritonitis during total duration of 7686 patient months (peritonitis rate of 1/53). This was 1/26 with a total 38 episodes of peritonitis during the total duration of 997 patient months (p=0.01) for EPS group. In regression analysis, PD duration, age at PD start and duration of UFF were associated with EPS.

Conclusions Longer time being on PD, younger age, and higher UFF duration were the risk factors for EPS development.